The chemistry and pharmacology of privileged pyrroloquinazolines.
The advent of next-generation sequencing (NGS) technology has plummeted the cost of whole genome sequencing, which has provided a long list of putative drug targets for a variety of diseases ranging from infectious diseases to cancers. The majority of these drug targets are still awaiting high-quality small molecule ligands to validate their therapeutic potential and track their druggability. Screening compound libraries based on privileged scaffolds is an efficient strategy to identify potential ligands to distinct biological targets. 7H-Pyrrolo[3,2-f]quinazoline (PQZ) is a potential privileged heterocyclic scaffold with diverse pharmacological properties. A number of biological targets have been identified for different derivatives of PQZ. This review summarized the synthetic strategies to access the chemical space associated with PQZ and discussed their unique biological profiles.
Program in Chemical Biology, Department of Physiology and Pharmacology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA.
Bo
B
Chao
Program in Chemical Biology, Department of Physiology and Pharmacology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA.
Bingbing X
BX
Li
Program in Chemical Biology, Department of Physiology and Pharmacology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, USA.
Xiangshu
X
Xiao